| sofosbuvir/velpatasvir / Generic mfg. |
2016-000599-87: Treatment for type 3 chronic hepatitis C virus infection: comparing 12 and 24 weeks of antiviral drugs - is longer therapy worthwhile? |
|
|
| Ongoing | 4 | 60 | Europe | Epclusa, Film-coated tablet, Epclusa | Queen Mary University of London, National Institute for Health Research | Adult patients chronically infected with genotype 3 hepatitis C virus with cirrhosis, Adults infected with hepatitis C virus (subtype 3) causing severe liver scaring and damage, Diseases [C] - Virus Diseases [C02] | | | | |
2016-003941-27: Epclusa blood concentrations after crushing the tablet compared to the whole tablet. |
|
|
| Ongoing | 4 | 14 | Europe | Tablet, Epclusa | Radboud University Medical Center, Radboud University Medical Center | hepatitis C virus, hepatitis C virus, Diseases [C] - Virus Diseases [C02] | | | | |
2017-001024-21: treatment of eradication of HCV infection in immigrant patients with innovative drug Trattamento di eradicazione dell'infezione da HCV in pazienti immigrati con farmaco innovativo |
|
|
| Ongoing | 4 | 6000 | Europe | EPCLUSA, 044928012, Coated tablet, EPCLUSA | A.O.U. Università degli Studi della Campania "Luigi Vanvitelli", Gilead Scinces, GILEAD SCIENCES | Chronic HCV hepatitis, all fibrosis epatite cronica da HCV, tutte le fibrosi, hepatitis C virus infection infezione da virus dell'epatite C, Diseases [C] - Virus Diseases [C02] | | | | |
2020-003879-18: Treatment of chronic hepatitis C in children aged 6 – 18 years using a direct-acting antiviral (sofosbuvir/velpatasvir) acting against all HCV genotypes Leczenie dzieci w wieku 6 – 18 lat z przewlekłym wirusowym zapaleniem wątroby typu C przy użyciu leku o bezpośrednim działaniu przeciwwirusowym działającego na wszystkie genotypy wirusa HCV |
|
|
| Not yet recruiting | 4 | 50 | Europe | Epclusa (sofosbuvir/velpatasvir), Epclusa sofosbuvir/velpatasvir), Tablet, Epclusa (Sofosbuvir/Velpatasvir) | Medical University of Warsaw, Medical Research Agency | Chronic hepatitis C Przewlekłe wirusowe zapalenie wątroby typu C, Chronic hepatitis C caused by hepatitis C virus (HCV) infection Przewlekłe wirusowe zapalenie wątroby typu C wywołane przez wirus HCV, Diseases [C] - Virus Diseases [C02] | | | | |
ACTRN12618001939280: Sofosbuvir/Velpatasvir and Mental Health Impact in people with Lived Experience and Hepatitis C infection - SMILE-C Trial |
|
|
| Terminated | 4 | 150 | | | The University of Adelaide, Gilead Sciences, Inc. | Hepatitis C virus infection, Schizophrenia, Schizoaffective disorder, Bipolar disorder, Cognitive dysfunction | | | | |
NCT06306300: Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil) |
|
|
| Recruiting | 4 | 30000 | RoW | Specialist - Epclusa 400Mg-100Mg Tablet, Standard-of-Care (SC) HCV treatment, Non- specialist - Epclusa 400Mg-100Mg Tablet, Simplified-and-Decentralized (SD) HCV treatment | Oswaldo Cruz Foundation, Conselho Nacional de Desenvolvimento Científico e Tecnológico | Hepatitis C | 12/25 | 12/25 | | |
NCT05264558: Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30% |
|
|
| Completed | 4 | 606 | RoW | Xpert HCV Viral load finger stick point of care test (Cepheid), Epclusa 400Mg-100Mg Tablet, Standard of care | Macfarlane Burnet Institute for Medical Research and Public Health Ltd, Cairns Hinterland Health Hospital and Health Services, The University of Queensland | Hepatitis C | 08/23 | 09/23 | | |
NCT05016609: Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) |
|
|
| Recruiting | 4 | 1800 | RoW | OraQuick HCV Antibody test (OraSure Technologies, Inc), Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid), Sofosbuvir/Velpatasvir (Gilead) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | Hepatitis C | 04/24 | 06/24 | | |
| Recruiting | 4 | 148 | US | Sofosbuvir/velpatasvir, Epclusa, Monitoring, Sofosbuvir/velpatasvir (Epclusa) | Brigham and Women's Hospital | Hepatitis C, Awaiting Organ Transplant | 12/23 | 12/23 | | |
BDTAF, NCT04997564: The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China |
|
|
| Recruiting | 4 | 120 | RoW | Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir | Peking University First Hospital | Chronic Hepatitis C, Chronic Hepatitis B | 12/23 | 12/23 | | |
| Recruiting | 4 | 100 | Canada, US | Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet, Epclusa | Catherine Anne Chappell, Gilead Sciences | Hepatitis C, Chronic, Pregnancy; Infection | 12/24 | 12/25 | | |
| Active, not recruiting | 4 | 374 | US | Sofosbuvir/velpatasvir (Epclusa®) | Jennifer Havens, National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), Gilead Sciences, University of Kentucky, Icahn School of Medicine at Mount Sinai, University of Bristol | Hepatitis C, Opioid-Related Disorders, Injection Drug Use | 08/24 | 12/24 | | |
NCT03520660: People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents |
|
|
| Active, not recruiting | 4 | 135 | US | Epclusa | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases | 12/32 | 12/32 | | |
IRCT20130812014333N1: Comparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir plus Velpatasvir” to “standard of care therapeutic regimen” in patients with COVID-19 |
|
|
| Recruiting | 3 | 80 | Kermanshah | sofosbuvir/velpatasvir - Generic mfg. | Gilead, Generic mfg., Kermanshah University of Medical Sciences | COVID-19 | | | | |
NCT03891550: Micro-elimination of Hepatitis C Virus Infection in Uremics |
|
|
| Active, not recruiting | 3 | 135 | RoW | Epclusa | Kaohsiung Medical University Chung-Ho Memorial Hospital | Hepatitis C | 04/24 | 04/24 | | |
2018-003640-23: PHASE II CLINICAL STUDY ON THE USE OF HCV+ DONORS FOR SOLID ORGAN TRANSPLANTATION. STUDIO CLINICO DI FASE II PER L'UTILIZZO DI DONATORI HCV+ A SCOPO DI TRAPIANTO. |
|
|
| Ongoing | 2 | 212 | Europe | EPCLUSA SOFOSBUVIR 400MG/VELPATASVIR 100MG, [1BV30D], Film-coated tablet, EPCLUSA | ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT | USE OF POSITIVE DONORS FOR INFECTION OF THE HEPATITIS VIRUS FOR THE TRANSPLANTATION OF SOLID ORGANS IN AN ENDEMIC AREA FOR HEPATITIS C WITH LOW RATE OF DONATIONS FROM CADAVERS: OPEN PHASE II CLINICAL STUDY. UTILIZZO DI DONATORI POSITIVI PER INFEZIONE DEL VIRUS DELL’EPATITE C PER IL TRAPIANTO DI ORGANI SOLIDI IN UN’AREA ENDEMICA PER EPATITE C CON BASSO TASSO DI DONAZIONI DA CADAVERE: STUDIO CLINICO MONOCENTRICO APERTO DI FASE II., HCV- patient to whom an organ from a HCV+ donor is transplanted who will receive Epclusa. Pazienti HCV- a cui venga trapiantato un organo da donatore HCV+ che verranno trattati con Epclusa., Diseases [C] - Digestive System Diseases [C06] | | | | |
| Completed | 2 | 40 | Europe | Ledipasvir+Sofosbuvir, Harvoni, Sofosbuvir+Velpatasvir, Epclusa | Fondazione Italiana Linfomi ONLUS | Indolent B-cell Lymphoma, Hepatitis C | 02/20 | 11/22 | | |
2018-003474-27: Multicenter trial for the treatment of acute Hepatitis C with Sofosbuvir/Velpatasvir |
|
|
| Not yet recruiting | 2 | 20 | Europe | Film-coated tablet, Epclusa® 400 mg/100 mg Filmtabletten | Hannover Medical School, Gilead Sciences, Inc., German Center for Infection Research (DZIF) | Adults with acute hepatitis C virus (HCV) infection, Adults with acute hepatitis C virus infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT03222531: Expanding the Pool in Orthotopic Heart Transplantation |
|
|
| Active, not recruiting | 2 | 20 | US | sofosbuvir/velpatasvir, Epclusa | Mary E. Keebler, MD | Hepatitis C, Heart Transplant, Cardiac Transplant | 12/24 | 12/24 | | |
TROJAN-C, NCT03383419: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients |
|
|
| Active, not recruiting | 2 | 15 | US | Epclusa | Baylor Research Institute | Heart Failure | 12/23 | 12/23 | | |
NCT03809533: The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients |
|
|
| Active, not recruiting | 2 | 30 | US | sofosbuvir/velpatasvir, Epclusa | Amit D Tevar, MD, University of Pittsburgh Medical Center | Kidney Transplantation, Hepatitis C | 05/24 | 05/24 | | |
NCT03819322: The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients |
|
|
| Active, not recruiting | 2 | 73 | US | sofosbuvir/velpatasvir, Epclusa | Naudia Jonassaint. MD, University of Pittsburgh Medical Center | Liver Transplant, Hepatitis C | 03/25 | 03/25 | | |
| Recruiting | 2 | 450 | US | Epclusa | University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | End Stage Renal Disease | 05/25 | 12/25 | | |
| Completed | 1/2 | 10 | US | Zepatier, Epclusa | University of Pennsylvania, Merck Sharp & Dohme LLC | Lung Diseases | 12/21 | 12/22 | | |
| Active, not recruiting | 1 | 26 | Canada | Sofosbuvir-velpatasvir (400 mg/100 mg), Epclusa, Ex Vivo Lung Perfusion (EVLP), Normothermic EVLP | University Health Network, Toronto, Gilead Sciences | Lung Transplant Infection, Hepatitis C | 01/20 | 12/24 | | |
NCT04382404: Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir |
|
|
| Completed | 1 | 11 | US | Sofosbuvir-Velpatasvir Drug Combination, Epclusa | Catherine Anne Chappell, Gilead Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Hepatitis C, Chronic | 10/23 | 10/23 | | |
| Not yet recruiting | 1 | 3040 | NA | sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus., OraQuick® HCV RDT | Médecins du Monde, UNITAID, Burnet Institute, University of Bristol, International Network of People who Use Drugs | Hepatitis C, RDT | 12/26 | 12/26 | | |
NCT04039698: Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil |
|
|
| Active, not recruiting | N/A | 144 | RoW | Telemedicine, Velpatasvir/Sofosbuvir, Epclusa | Hospital de Clinicas de Porto Alegre, Ministry of Health, Brazil, State Secretary of Health of Rio Grande do Sul, TelessaúdeRS / UFRGS | Chronic Hepatitis C | 12/20 | 11/21 | | |
ChiCTR1800020246: Study for Antiviral Therapy of Patients Co-infected with HIV and HCV |
|
|
| Not yet recruiting | N/A | 600 | | Epclusa@(Sofosbuvir/ velpatasvir)(po) ;Genvoya@(elvitegravir 150mg/cobicistat150mg/emtricitabine200mg/tenofovir alafenamide10mg)(po) | Guangzhou Eighth People's Hospital; Level of the institution：, The Thirteenth Five-Year Plan National Science and Technology Major Project Sub-study 3 | HIV/HCV Co infactiong | | | | |
SCALE-C, NCT03776760: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination |
|
|
| Recruiting | N/A | 600 | RoW | Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, Epclusa, glecaprevir/pibrentasvir, Maviret | Kirby Institute, South Australian Health and Medical Research Institute, Flinders University | Hepatitis C, Hepatitis, Liver Diseases, Hepatitis, Viral, Human, RNA Virus Infections, Digestive System Diseases | 08/22 | 08/22 | | |
| Not yet recruiting | N/A | 1000 | NA | Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa], Epclusa | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Gilead Sciences | Hepatitis C in Substance Users | 08/23 | 05/24 | | |
ChiCTR1900027793: Two direct antiviral drugs in the clinical effect of reverse c liver fibrosis multicenter prospectie cohort study |
|
|
| Not yet recruiting | N/A | 280 | | Grazoprevir/elbasvir ;Sofosbuvir and velpatasvir | Department of Gastroenterology, Xinqiao Hospital, Affiliated to Military Medical University; Xinqiao Hospital of Army Military University, Self-raised | Chronic hepatitis c | | | | |
NCT05248919: Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan |
|
|
| Enrolling by invitation | N/A | 318 | RoW | Epclusa (nucleotide HCV NS5B polymerase inhibitors)., Sofosbuvir 400 Mg and Velpatasvir 100 Mg Oral Capsules | Queen Mary University of London, Aga Khan University, Dow University of Health Sciences, University of Oxford, University of Bristol | Hepatitis C | 09/24 | 12/24 | | |
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C |
|
|
| Recruiting | N/A | 300 | RoW | Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir | Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis C, Chronic | 07/21 | 08/21 | | |
NCT04948801: SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients |
|
|
| Recruiting | N/A | 150 | RoW | Epclusa (sofosbuvir and velpatasvir) | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis C | 12/21 | 12/21 | | |
| Recruiting | N/A | 300 | Canada | Epclusa | Vancouver Infectious Diseases Centre | Hepatitis C, Chronic, Drug Use | 12/23 | 12/24 | | |
